Jiangsu Hengrui Medicine Co., Ltd
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 105
- Registration Number
- NCT06368167
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China
Study of the Food Effects of Herombopag Olamine Tablets in Healthy Subjects.
- Conditions
- Adult Patients With Chronic Primary ITPAdult Patients With SAA Who do Not Respond Well to Immunosuppressive Therapy
- Interventions
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT06346925
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical Uniersity, Hefei, Anhui, China
A Study of Bupivacaine Liposome Injection in Local Analgesia of Pediatric Patients
- Conditions
- Local Analgesia Via Infiltration
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 232
- Registration Number
- NCT06344091
- Locations
- 🇨🇳
Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, China
Randomized, Double-blind, Placebo-controlled Study of RSS0393 Ointment in Healthy and Psoriatic Subjects
- Conditions
- HealthyPsoriatic Subjects
- Interventions
- Drug: RSS0393 ointment；Placebo
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 98
- Registration Number
- NCT06308393
- Locations
- 🇨🇳
The First Affiliated Hospital of University of Science and Technology of China (USTC)., Hefei, Anhui, China
🇨🇳Huashan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer
- Conditions
- Recurrent Ovarian Cancer
- Interventions
- Drug: Bevacizumab； HRS-1167
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT06308406
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi, China
A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies
- Conditions
- Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk
- Interventions
- Drug: HHPG-19K Injection
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 107
- Registration Number
- NCT06254742
- Locations
- 🇨🇳
Henan Cancer Hospita, Zhengzhou, Henan, China
A Study of Remimazolam Tosilate for Sedation in the ICU
- Conditions
- Sedation in the ICU
- Interventions
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 214
- Registration Number
- NCT06222294
- Locations
- 🇨🇳
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
A Study of Remimazolam Tosilate for Sedation in Non-intubated Diagnostic and Therapeutic Procedures
- Conditions
- Sedation in Non-intubated Diagnostic and Therapeutic Procedures
- Interventions
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06216444
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
A SHR0302 BA Study on Healthy Subjects
- Conditions
- Autoimmune Diseases
- Interventions
- Drug: SHR0302 quick release tabletsDrug: SHR0302 sustained-release tablets
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT06202612
- Locations
- 🇨🇳
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy Subjects
- First Posted Date
- 2024-01-10
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT06198556
- Locations
- 🇨🇳
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China